Imflifidase shows robust efficacy results in phase 2 among patients with severe GBS. This is an orphan indication, and GBS is an acute disease in patients that tends to become non-ambulatory within weeks rapidly. If approved, Imflifidase will expand into a dynamic market. We increase our base case to SEK 130 from 125 (Bull SEK 250, Bear SEK 15).

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se